| | Pfizer announced the M&A event of the year with its Biohaven acquisition. Top investors turned to Tegus for on-demand insight on Nurtec’s trajectory, Biohaven’s leadership, and the competitive environment. See for yourself with a free Tegus trial. |
US to provide Bavarian Nordic's vaccine Jynneos to some at risk for monkeypox, CDC says Surgeon general issues landmark report with new solutions to combat crippling worker burnout issue When will biotech markets get better? BridgeBio fears they may stay 'pretty bad' until 2024 Dexcom, Insulet in talks to merge into a diabetes device behemoth: report Moderna CEO Bancel uses inaugural stock option to give $355M to charity Pfizer's Arena goal? Get out of the way and don't 'break the new toy' Howard University, Teva Pharmaceuticals launch coalition to advocate for equity through digital health Illumina obtains European companion diagnostic test approval for Bayer rare cancer drug Vitrakvi Boing! SpringWorks' stock jumps as phase 3 tumor trial hits goal J&J's crown jewel Stelara faces another potential rival as biosim player Alvotech touts trial win AHA presses for False Claims Act probes to target payers over Medicare Advantage denials Know Labs bulks up C-suite to prep for FDA review of noninvasive glucose monitor Teva's halt at troubled plant threatens to create shortages in wide range of injectable meds: report AstraZeneca collects 2nd pulmonary fibrosis target from BenevolentAI collaboration Featured Story | By Kevin Dunleavy In response to the threat of a spread of monkeypox, the United States will provide doses of the Jynneos vaccine to some at-risk adults. The U.S. has a stockpile of more than 1,000 doses of the vaccine, according to the CDC. read more |
| |
|---|
|
Top Stories By Robert King A new advisory from the U.S. surgeon general is pressing for stakeholders to alleviate healthcare worker burnout by reducing administrative and other burdens and improve access to mental health services. read more By Nick Paul Taylor BridgeBio Pharma is digging in for a prolonged bear market. Since suffering a phase 3 flop late last year, the biotech has taken a series of steps to extend its cash runway, reflecting its CEO’s belief that markets could “stay pretty bad up until the end of next year”. read more By Andrea Park Diabetes devicemakers Dexcom and Insulet have already aligned their product lines—with Insulet’s Omnipod insulin pumps designed to be used alongside Dexcom’s continuous glucose monitors—and soon that may become much more permanent. read more By Fraiser Kansteiner Stéphane Bancel, who joined Moderna back in 2013, is cashing out his original stock options in the company for charity, the biotech’s helmsman said Tuesday. All told, Bancel expects the move to yield a donation of about $355 million, after some $280 million in state and federal tax payments. read more By Annalee Armstrong Five months after Pfizer bought Arena, the team has delivered: Etrasimod, the immuno-inflammatory disease therapy that attracted the buyout, has been linked to a 27% remission rate in patients with ulcerative colitis in a phase 3 clinical trial. read more By Anastassia Gliadkovskaya The group plans to advocate for improved access to care through digital health innovations and to be a hub of resources on the importance of digital health equity. read more By Conor Hale Biopsy results from Illumina's TruSight Oncology Comprehensive test can now be used to identify patients with any solid tumors that harbor NTRK gene mutations. read more By Nick Paul Taylor SpringWorks Therapeutics is bouncing to the FDA. With a phase 3 desmoid tumor trial hitting its primary and secondary endpoints, the Pfizer spinout is planning to seek approval for nirogacestat in the second half of the year. read more By Zoey Becker In the last year of Johnson & Johnson's Stelara patent, companies are lining up to produce biosimilars. Alvotech, already armed with a promising Humira biosimilar in its pipeline, found therapeutic equivalence between its Stelara copycat and J&J's top product. read more By Robert King The AHA wrote to the Justice Department seeking a new task force to investigate potential False Claims Act violations from Medicare Advantage plans. read more By Andrea Park As it gears up to submit its noninvasive glucose monitoring technology for potential FDA clearance, Know Labs has recruited a pair of experts to its executive team to help smooth out the process. read more By Joseph Keenan The shuttering of Teva’s long troubled manufacturing facility in Irvine, California, may create shortages of up to 24 generic sterile injectable drugs, including five essential medications of which the company supplied more than 15% of the market last year, according to an industry group. read more By Conor Hale After securing targets in chronic kidney disease and idiopathic pulmonary fibrosis (IPF), AstraZeneca is collecting a second IPF target from its recently reupped collaboration with BenevolentAI. read more | 